Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877066 | 0.86 | BCHE (0.40) | RAB9AKMT2ANPC1ALDH1A1PKM | |
| SCHEMBL20838307 | 0.85 | MEN1 (0.51) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL4872668 | 0.84 | PLA2G2A (0.45) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL4880376 | 0.83 | SMN1; SMN2 (0.44) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL4872533 | 0.83 | SMN1; SMN2 (0.44) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL2527537 | 0.83 | FFAR1 (0.41) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL644797 | 0.82 | FFAR1 (0.49) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL4878837 | 0.81 | PLA2G2A (0.47) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL4868621 | 0.78 | PLA2G2A (0.45) | PLA2G2ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL2529384 | 0.78 | KDM4E (0.47) | PLA2G2ARAB9AKMT2AMEN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | PLA2G2A 4230/4885RAB9A 2224/4885KMT2A 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.